PTX-400 / PanTheryx - LARVOL DELTA

Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study. (PubMed, Int Immunopharmacol) - P2 | "PTX may be suggested as a promising adjuvant anti-inflammatory medication for Parkinson's disease treatment."

Journal • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • AMPK • HMGB1 • mTOR

Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study. (PubMed, Inflammopharmacology) - P2 | "PTX could alleviate inflammation in patients with UC, so it might be promising adjunctive for patients with UC."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Pain • Ulcerative Colitis • IL6 • MPO • STAT3 • TCF3 • TJP1 • TNFA

Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia. (PubMed, Pathogens) - "Seventy-three patients aged 18-65 years, having multiple lesions or a single lesion ≥ 3 cm were randomized to receive: intramuscular MA (20 mg/kg/day × 20 days) plus oral PTX 400 mg thrice daily (intervention arm, n = 36) or MA plus placebo (control arm, n = 37), between 2012 and 2015. However, therapeutic failure was associated with significant overexpression of il1β and ptgs2 (p < 0.05), irrespective of study group. No clinical benefit of addition of PTX to standard treatment was detected in early mild to moderate CL caused by Leishmania (V.) panamensis."

Clinical • Journal • Dermatology • Immune Modulation • Infectious Disease • Inflammation • IL1B • PTGS2

A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients. (PubMed, Eur Rev Med Pharmacol Sci) - "Treatment with Vit. E, UDCA and PTX was both safe and effective in improving hepatic aminotransferases and inflammatory markers in Egyptian NASH patients. The superior effect of Vit. E compared to UDCA and PTX may suggest that oxidative stress plays a key role in disease progression of NASH patients. Moreover, IL6 and CCL2/MCP-1 may be used with or without ALT for treatment evaluation of NASH people."

Clinical • Journal • Hepatology • Non-alcoholic Steatohepatitis • CCL2 • IL6